IP Library Granted Patent US 10,689,462
Granted Patent B2
US 10,689,462 · App. 15/978,872 · Granted Jun 23, 2020

Therapeutic and imaging compositions and uses thereof

Inventors: David H. Thompson (West Lafayette, IN); Aditya Kulkarni (West Lafayette, IN); Christopher Collins (West Lafayette, IN); Yawo Mondjinou (West Lafayette, IN)
Assignee: Purdue Research Foundation
C08B37/0015A61K31/724A61K31/765A61K47/60A61K47/61A61K47/6951A61K51/065A61K51/1268G01N33/6893A61K47/547C08G83/007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,689,462
App. No.
15/978,872
Granted
Jun 23, 2020
Kind
B2
Abstract

Various embodiments of the present invention are directed to polyrotaxanes comprising a poloxamer core and at least one cyclodextrin and methods for treating Niemann-Pick type C (NPC) and imaging (e.g., MRI) using the polyrotaxanes various embodiments of the present invention.

Claims (22)

1. A polyrotaxane comprising the general formula:

or a salt thereof,

wherein:

n is an integer from 1 to 30;

C and C′ are the same or different and represent endcapping groups of the formula:

wherein:

L 1 is a (C 1 -C 6 )hydrocarbylene group,

G 1 and G 2 , together, form a radical having the formula:

wherein each L 2 is independently a bond or acyl; each G 3 is a substituted or unsubstituted (C 6 -C 50 )hydrocarbyl group, interrupted by 0 to 5 groups chosen from —O—, —NH—, and —S—; and

each s is independently an integer from 1 to 5; and

t is an integer from 2 to 5:

B is a poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) (PEG-PPG-PEG) triblock copolymer; and

A is a beta cyclodextrin;

wherein G 3 is not a substituted or unsubstituted (C 6 -C 12 )aryl group.

2. The polyrotaxane of claim 1 , wherein G 3 is a substituted or unsubstituted —O—(C 6 -C 50 )alkyl group.

3. The polyrotaxane of claim 1 , wherein G 3 is a cholesteryl group.

4. The polyrotaxane of claim 1 , wherein n is an integer from 5 to 15.

5. The polyrotaxane of claim 1 , wherein n is an integer from 3 to 11.

6. A pharmaceutical composition comprising the polyrotaxane of claim 1 and a pharmaceutically acceptable carrier.

7. The polyrotaxane of claim 1 , wherein the poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) (PEG-PPG-PEG) triblock copolymer has the formula:

wherein each R 5 is methyl; d is an integer from about 100 to about 800; and q is an integer from about 100 to about 800.

8. The polyrotaxane of claim 7 , wherein d+q is from about 100 to about 800.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 16, 2018
From: PURDUE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046545/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2018
From: THOMPSON, DAVID H.; KULKARNI, ADITYA; COLLINS, CHRISTOPHER; MONDJINOU, YAWO
To: PURDUE RESEARCH FOUNDATION
Reel/Frame 046003/0753 →
Continuity (4)
Continuation 14889722
Provisional Application 61820658 · May 7, 2013
Provisional Application 61820597 · May 7, 2013
Related Publication 20180258192A1 · Sep 13, 2018